SB939

DRUG4 trials

Sponsors

S*BIO, NCIC Clinical Trials Group, M.D. Anderson Cancer Center

Conditions

Hematologic MalignanciesLeukemiaMetastatic SarcomaMyelodysplastic SyndromeMyeloproliferative DisordersSolid TumorsSolid Tumours

Phase 1

A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine

CompletedNCT00741234

S*BIOHematologic Malignancies, Myelodysplastic Syndrome, Solid Tumors

Start: 2007-04-30End: 2012-03-31Updated: 2012-04-23

A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia

CompletedNCT01184274

NCIC Clinical Trials GroupLeukemia, Solid Tumours

Start: 2010-10-01End: 2014-01-16Updated: 2023-08-04

Phase 2

A Study of SB939 in Patients With Translocation-Associated Recurrent/Metastatic Sarcomas

CompletedNCT01112384

NCIC Clinical Trials GroupMetastatic Sarcoma

Start: 2010-10-21End: 2014-01-16Updated: 2023-08-04

Study of SB939 in Subjects With Myelofibrosis

CompletedNCT01200498

M.D. Anderson Cancer CenterMyeloproliferative Disorders

Start: 2010-11-30End: 2012-11-30Updated: 2014-01-30

Related Papers

A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200†.

2015-01-2841 citations